ACTRIMS 2021 | A case of dermatographism with ocrelizumab use in MS

Jennifer Graves, MD, PhD, MAS, University of California San Diego School of Medicine, San Diego, CA, discusses a case of dermatographism associated with ocrelizumab use, an anti-CD20 monoclonal antibody, in a patient with relapsing-remitting multiple sclerosis (MS). Dermatographism causes exaggerated wealing in response to light touch or pressure and has not previously been reported with ocrelizumab use. This case highlights a potential adverse effect of the treatment and may help understand the causes of dermatographism. This interview took place during the ACTRIMS Forum 2021.